ES2176235T3 - Pirazolitriazinas con actividad inhibidora de la interleuquina-1 y delfactor de necrosis tumoral. - Google Patents

Pirazolitriazinas con actividad inhibidora de la interleuquina-1 y delfactor de necrosis tumoral.

Info

Publication number
ES2176235T3
ES2176235T3 ES94906381T ES94906381T ES2176235T3 ES 2176235 T3 ES2176235 T3 ES 2176235T3 ES 94906381 T ES94906381 T ES 94906381T ES 94906381 T ES94906381 T ES 94906381T ES 2176235 T3 ES2176235 T3 ES 2176235T3
Authority
ES
Spain
Prior art keywords
alkyl
suitable substituent
pct
pirazolitriazinas
interleuquine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94906381T
Other languages
English (en)
Inventor
Yoshio Kawai
Hitoshi Yamazaki
Hirokazu Tanaka
Teruo Oku
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2176235T3 publication Critical patent/ES2176235T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

NUEVOS DERIVADOS HETEROCICLICOS DE FORMULA (I) EN DONDE R{SUP,1} ES ARILO QUE PUEDE TENER SUSTITUYENTE(S) ADECUADO(S) O UN GRUPO HETEROCICLICO QUE PUEDE TENER SUSTITUYENTE(S) ADECUADO(S), R{SUP,2} ES ARILO QUE PUEDE TENER SUSTITUYENTE(S) ADECUADO(S) O UN GRUPO HETEROCICLICO QUE PUEDE TENER SUSTITUYENTE(S) ADECUADO(S), R{SUP,3} ES HIDROGENO O ACILO, R{SUP,4} ES HIDROGENO, ALKILO BAJO, CICLOALKILO(()BAJO()), CICLOALKILO(()BAJO())-ALKILO(()BAJO()), CARBOXIALKILO(()BAJO()), CARBOXIALKILO(()BAJO()) PROTEGIDO, ARALKILO(()BAJO(() QUE PUEDE TENER SUSTITUYENTE(S) ADECUADO(S), ARALKENILO(()BAJO()), TRICICLIALKILO UNIDO, UN GRUPO HETEROCICLICO QUE PUEDE TENER SUSTITUYENTE(S) ADECUADO(S), ACILO, O UN GRUPO DE FORMULA (B) (EN EL QUE A ES ALQUILENO BAJO), Y R{SUP,5} ES HIDROGENO O ALKILO BAJO, Y UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO QUE SON UTILES COMO INHIBIDORES DE INTERLEUQUINA-1 Y NECROSIS TUMORAL.
ES94906381T 1993-02-26 1994-02-09 Pirazolitriazinas con actividad inhibidora de la interleuquina-1 y delfactor de necrosis tumoral. Expired - Lifetime ES2176235T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939303993A GB9303993D0 (en) 1993-02-26 1993-02-26 New heterocyclic derivatives

Publications (1)

Publication Number Publication Date
ES2176235T3 true ES2176235T3 (es) 2002-12-01

Family

ID=10731142

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94906381T Expired - Lifetime ES2176235T3 (es) 1993-02-26 1994-02-09 Pirazolitriazinas con actividad inhibidora de la interleuquina-1 y delfactor de necrosis tumoral.

Country Status (20)

Country Link
US (1) US5670503A (es)
EP (1) EP0686156B1 (es)
JP (1) JP3569917B2 (es)
KR (1) KR100313615B1 (es)
CN (1) CN1041929C (es)
AT (1) ATE220677T1 (es)
AU (1) AU681625B2 (es)
CA (1) CA2156919A1 (es)
DE (1) DE69430988T2 (es)
DK (1) DK0686156T3 (es)
ES (1) ES2176235T3 (es)
GB (1) GB9303993D0 (es)
HU (1) HUT70832A (es)
IL (1) IL108562A (es)
MX (1) MX9401408A (es)
PT (1) PT686156E (es)
RU (1) RU2124517C1 (es)
TW (1) TW260669B (es)
WO (1) WO1994019350A1 (es)
ZA (1) ZA94787B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU736854B2 (en) 1996-04-25 2001-08-02 Nissan Chemical Industries Ltd. Ethylene derivatives and pesticides containing said derivatives
EP1019394A1 (en) 1997-05-22 2000-07-19 G.D. Searle & Co. PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
DE69835518T2 (de) 1997-06-12 2007-08-09 Aventis Pharma Ltd., West Malling Imidazolyl-cyclische acetale
AU7966198A (en) 1997-06-13 1998-12-30 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
ATE293603T1 (de) * 1997-10-14 2005-05-15 Mitsubishi Pharma Corp Piperazin-verbindungen und ihre medizinische verwendung
AU1924699A (en) 1997-12-19 1999-07-12 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositionsand uses
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
CA2341370A1 (en) * 1998-08-20 2000-03-02 Smithkline Beecham Corporation Novel substituted triazole compounds
DE69914357T2 (de) 1998-11-04 2004-11-11 Smithkline Beecham Corp. Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine
WO2001015525A1 (en) * 1999-08-31 2001-03-08 Fujisawa Pharmaceutical Co., Ltd. Organ preservatives
ES2237470T3 (es) * 1999-11-10 2005-08-01 Ortho-Mcneil Pharmaceutical, Inc. 2-aril-3-(heteroaril)-imidazo(1,2-alfa)pirimidinas sustituidas; y composiciones farmaceuticas y procedimientos asociados.
US7253169B2 (en) * 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
US6417189B1 (en) * 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
EP1233950B1 (en) 1999-11-23 2005-10-05 Smithkline Beecham Corporation 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/P39 kINASE INHIBITORS
JP2003514900A (ja) 1999-11-23 2003-04-22 スミスクライン・ビーチャム・コーポレイション ＣＳＢＰ／ｐ３８キナーゼ阻害剤としての３，４−ジヒドロ−（１Ｈ）−キナゾリン−２−オン化合物
ATE281439T1 (de) 1999-11-23 2004-11-15 Smithkline Beecham Corp 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
CN100525768C (zh) 2000-10-23 2009-08-12 史密丝克莱恩比彻姆公司 新化合物
RU2316556C2 (ru) * 2000-11-17 2008-02-10 Бристол-Маерс Сквибб Компани СПОСОБЫ ЛЕЧЕНИЯ СОСТОЯНИЙ, ОБУСЛОВЛЕННЫХ p38 КИНАЗАМИ, И ПИРРОЛОТРИАЗИНОВЫЕ СОЕДИНЕНИЯ, ПРИМЕНИМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗ
WO2002064592A1 (en) * 2000-12-28 2002-08-22 Neurocrine Biosciences, Inc. Tricyclic crf receptor antagonists
SK287857B6 (sk) * 2001-05-24 2012-01-04 Eli Lilly And Company Novel pyrrole derivatives as pharmaceutical agents
US6821971B2 (en) * 2001-09-20 2004-11-23 The Procter & Gamble Company Fused pyrazolone compounds which inhibit the release of inflammatory cytokines
KR20040103972A (ko) 2002-04-19 2004-12-09 스미스클라인 비참 코포레이션 신규 화합물
ES2278170T3 (es) 2002-07-09 2007-08-01 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Composiciones farmaceuticas de anticolinergicos e inhibidores de la quinasa p38 en el tratamiento de enfermedades respiratorias.
EP1572113B1 (en) * 2002-08-26 2017-05-17 Takeda Pharmaceutical Company Limited Calcium receptor modulating compound and use thereof
AU2004210127B2 (en) 2003-01-27 2009-10-01 Merck Sharp & Dohme Corp. Substituted pyrazoles, compositions containing such compounds and methods of use
NZ551405A (en) * 2004-06-04 2009-06-26 Merck & Co Inc Pyrazole derivatives, compositions containing such compounds and methods of use
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
US20080096905A1 (en) 2005-03-25 2008-04-24 Glaxo Group Limited Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives
US7423042B2 (en) 2005-03-25 2008-09-09 Glaxo Group Limited Compounds
MY145343A (en) 2005-03-25 2012-01-31 Glaxo Group Ltd Novel compounds
PE20061193A1 (es) 2005-03-25 2006-12-02 Glaxo Group Ltd DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
CN101300232A (zh) * 2005-07-26 2008-11-05 默克公司 合成取代的吡唑的方法
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
US20110195962A1 (en) * 2007-08-16 2011-08-11 Alcon Research, Ltd. Use of multi-pharmacophore compounds to treat nasal disorders
JP2010540451A (ja) * 2007-09-20 2010-12-24 ワイス・エルエルシー ピラゾロ［５，１−ｃ］［１，２，４］トリアジン、その調製法および使用法
CN101441969B (zh) 2007-11-23 2010-07-28 清华大学 场发射像素管
CN101441972B (zh) 2007-11-23 2011-01-26 鸿富锦精密工业（深圳）有限公司 场发射像素管
EP2402344A1 (en) * 2010-06-29 2012-01-04 Basf Se Pyrazole fused bicyclic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06502178A (ja) * 1990-12-31 1994-03-10 藤沢薬品工業株式会社 イミダゾトリアジン誘導体
US5356897A (en) * 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines

Also Published As

Publication number Publication date
JP3569917B2 (ja) 2004-09-29
AU681625B2 (en) 1997-09-04
HUT70832A (en) 1995-11-28
KR100313615B1 (ko) 2002-05-30
MX9401408A (es) 1994-08-31
CN1120840A (zh) 1996-04-17
KR960701055A (ko) 1996-02-24
GB9303993D0 (en) 1993-04-14
HU9402459D0 (en) 1994-11-28
DK0686156T3 (da) 2002-11-11
PT686156E (pt) 2002-12-31
AU6010894A (en) 1994-09-14
IL108562A0 (en) 1994-05-30
EP0686156B1 (en) 2002-07-17
EP0686156A1 (en) 1995-12-13
ATE220677T1 (de) 2002-08-15
ZA94787B (en) 1994-09-08
IL108562A (en) 1997-06-10
CA2156919A1 (en) 1994-09-01
JPH08507056A (ja) 1996-07-30
DE69430988T2 (de) 2002-11-28
RU2124517C1 (ru) 1999-01-10
WO1994019350A1 (en) 1994-09-01
US5670503A (en) 1997-09-23
DE69430988D1 (de) 2002-08-22
TW260669B (es) 1995-10-21
CN1041929C (zh) 1999-02-03

Similar Documents

Publication Publication Date Title
ES2176235T3 (es) Pirazolitriazinas con actividad inhibidora de la interleuquina-1 y delfactor de necrosis tumoral.
MX9800577A (es) Derivados de 4,5-diaril oxazol.
GR3034542T3 (en) 4,5-diaryloxazole derivatives
NO940737L (es)
ATE195117T1 (de) 1-amdinophenyl-pyrrolidone/piperidinone als blutblättchen-aggregations inhibitoren
BR9606547A (pt) Novos derivados de pirimidona com atividade fungicida
AU1070895A (en) Indole-derived arylpiperazines as ligands for 5HT1-like receptors 5HT1B and 5HT1D
GB9602029D0 (en) New heterocyclic compounds
TW225513B (es)
HUP0103303A2 (hu) Imidazolvegyületek, eljárás előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
ES2141827T3 (es) Peptidos que tienen actividad antagonista de endotelina, su preparacion y composiciones farmaceuticas de los mismos.
AUPN952696A0 (en) New heterocyclic compounds
ATE155791T1 (de) Etoposid-derivate, ihre herstellung, ihre verwendung als medikament und ihre verwendung zur herstellung eines antikrebsmittels
ATE255102T1 (de) Benzothiophenderivate, ihre herstellung und verwendung als urokinase-inhibitoren
DE69124519D1 (de) Spiro[cycloalkylbenzen-1,1'-(1',2',3',4'-tetrahydroisoquinoline)] mit neuroprotektiven eigenschaften
CA2198875A1 (en) Quinazolinone pharmaceuticals and use thereof